טוען...
1963. PrEP Significantly Reduces the Rate of New HIV Diagnoses in US Metropolitan Statistical Areas Independent of Treatment as Prevention (2012–2017)
BACKGROUND: Tenofovir/Emtricitabine (TVD) was approved for a Pre-exposure Prophylaxis (PrEP) indication in the United States in July 2012. Biomedical HIV prevention tools can impact the rate of new HIV diagnoses but their relative contributions have not been described. METHODS: The analysis utilized...
שמור ב:
| הוצא לאור ב: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6808906/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz359.140 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|